The Michael J. Fox Foundation, one of the largest and most influential Parkinson’s organizations in the world, created an original article on the U.S. Food and Drug Administration’s (FDA) application acceptance of XEOMIN® for sialorrhea in adult Parkinson’s patients.
The Foundation’s VP of Medical Communications Rachel Dolhun MD wrote XEOMIN would “be the first and only therapy” indicated for adult sialorrhea in Parkinson’s patients. Though some treatments are used today, Dolhun stressed the limited choice that physicians face as no indicated therapy currently exists in the market. This would change with the anticipated approval of XEOMIN for adult sialorrhea at the end of 2018.
The article details the everyday impact that sialorrhea can have on patients – from social embarrassment, negative social interactions to physical symptoms such as skin irritation and possibly infection.
The Foundation is a key advocate in finding a cure for Parkinson’s disease, with over $750 million in funding contributions to research since 2000. It was founded by the renowned American actor Michael J. Fox, who has brought tremendous awareness and attention to the disease as he himself was diagnosed with Parkinson’s at age 29.
You can find the full article here: “Ask the MD: Potential Treatment for Drooling in Parkinson's”.